News & Events News SalubrisBio parent company Salubris Pharmaceuticals announces IND approval of JK07 Phase I study in China 20200921 SalubrisBio parent company Salubris Pharmaceuticals announces $265M investment from the Carlyle Group to further innovative R&D 20200901 SalubrisBio announces IND approval by FDA of JK07 Phase I study in the US 20200224 SalubrisBio parent company Salubris Pharmaceuticals announces partnership with JT Pharmaceuticals (Tokyo, Japan) to commercialize HIF-PH inhibitor enarodustat for the treatment of renal anemia in China: 20191225 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $10M in Viracta Therapeutics (San Diego, USA) to support development of their kick-and-kill combination cancer therapy 20181204 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $20M in MedAlliance SA (Nyon, Switzerland) to support development of their novel sirolimus-coated balloon for coronary and peripheral vascular diseases 20180522 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $8M in Mercator Medsystems (Emeryville, USA) to support development of their novel microinjection platform technology 20180621 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $5M in GO Therapeutics (Cambridge, USA) to support development of their novel microinjection platform technology 20180621 Upcoming Events Please check back soon for future events June 2-6, 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 2023 May 20-23, 2023 European Society of Cardiology’s Heart Failure (ESC-HF) Congress 2023 April 14-19, 2023 American Association for Cancer Research (AACR) Annual Meeting 2023
